retigabine/ezogabine
PreclinicalSmall molecule
GSKretigabine/ezogabine is one of 18 small molecule programs targeting Partial Epilepsy. It is currently in Preclinical.
1
Indications
3
Total Trials
0
Active Trials
17
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
17 competitors in Partial Epilepsy
#DrugCompanyPhaseTrials
1Keppra
UCBApproved
Trileptal
NovartisApproved
Vimpat
UCBApproved
Depakote
AbbVieApproved
Lyrica
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Zonegran
AAzurity Pharmaceuticals
Approved
Fycompa
CCatalyst Biosciences
Approved
Neurontin
VViatris Specialty LLC
Approved
Procardia
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Valium
Akero TherapeuticsApproved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Pediatric1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for retigabine/ezogabine. EMBL-EBI & Wellcome Sanger Institute.
- [4]